In early 2001, a Phase I/Early Phase II clinical trial was designed to test the dose, tolerability, and efficacy of the PDE4 inhibitor, rolipram as a treatment against CNS inflammation for MS patients (177). The gene discussed is PDE4A; the disease is myeloid sarcoma.